Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13


High-content analysis to leverage a robust phenotypic profiling approach to vascular modulation.

Isherwood BJ, Walls RE, Roberts ME, Houslay TM, Brave SR, Barry ST, Carragher NO.

J Biomol Screen. 2013 Dec;18(10):1246-59. doi: 10.1177/1087057113499775. Epub 2013 Oct 9.


AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo.

Loddick SA, Ross SJ, Thomason AG, Robinson DM, Walker GE, Dunkley TP, Brave SR, Broadbent N, Stratton NC, Trueman D, Mouchet E, Shaheen FS, Jacobs VN, Cumberbatch M, Wilson J, Jones RD, Bradbury RH, Rabow A, Gaughan L, Womack C, Barry ST, Robson CN, Critchlow SE, Wedge SR, Brooks AN.

Mol Cancer Ther. 2013 Sep;12(9):1715-27. doi: 10.1158/1535-7163.MCT-12-1174. Epub 2013 Jul 16.


Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer.

Brave SR, Odedra R, James NH, Smith NR, Marshall GB, Acheson KL, Baker D, Howard Z, Jackson L, Ratcliffe K, Wainwright A, Lovick SC, Hickinson DM, Wilkinson RW, Barry ST, Speake G, Ryan AJ.

Int J Oncol. 2011 Jul;39(1):271-8. doi: 10.3892/ijo.2011.1022. Epub 2011 Apr 29.


Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family.

Brave SR, Ratcliffe K, Wilson Z, James NH, Ashton S, Wainwright A, Kendrew J, Dudley P, Broadbent N, Sproat G, Taylor S, Barnes C, Silva JC, Farnsworth CL, Hennequin L, Ogilvie DJ, J├╝rgensmeier JM, Shibuya M, Wedge SR, Barry ST.

Mol Cancer Ther. 2011 May;10(5):861-73. doi: 10.1158/1535-7163.MCT-10-0976. Epub 2011 Mar 25.


Placental growth factor neutralising antibodies give limited anti-angiogenic effects in an in vitro organotypic angiogenesis model.

Brave SR, Eberlein C, Shibuya M, Wedge SR, Barry ST.

Angiogenesis. 2010 Dec;13(4):337-47. doi: 10.1007/s10456-010-9190-0. Epub 2010 Oct 16.


AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.

Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, Smith NR, James NH, Dukes M, Curwen JO, Chester R, Jackson JA, Boffey SJ, Kilburn LL, Barnett S, Richmond GH, Wadsworth PF, Walker M, Bigley AL, Taylor ST, Cooper L, Beck S, J├╝rgensmeier JM, Ogilvie DJ.

Cancer Res. 2005 May 15;65(10):4389-400.


The nitrergic transmitter of the anococcygeus--NO or not?

Gibson A, Brave SR, McFadzean I, Tucker JF, Wayman C.

Arch Int Pharmacodyn Ther. 1995 Jan-Feb;329(1):39-51. Review.


Nitrergic stimulation does not inhibit carbachol-induced inositol phosphate generation in the rat anococcygeus.

Gibson A, Brave SR, McFadzean I, Mirzazadeh S, Tucker JF, Wayman C.

Neurosci Lett. 1994 Aug 29;178(1):35-8.


Localisation of nitric oxide synthase within non-adrenergic, non-cholinergic nerves in the mouse anococcygeus.

Brave SR, Tucker JF, Gibson A, Bishop AE, Riveros-Moreno V, Moncada S, Polak JM.

Neurosci Lett. 1993 Oct 14;161(1):93-6.


An investigation of some S-nitrosothiols, and of hydroxy-arginine, on the mouse anococcygeus.

Gibson A, Babbedge R, Brave SR, Hart SL, Hobbs AJ, Tucker JF, Wallace P, Moore PK.

Br J Pharmacol. 1992 Nov;107(3):715-21.


L-NG-nitro arginine inhibits non-adrenergic, non-cholinergic relaxations of guinea-pig isolated tracheal smooth muscle.

Tucker JF, Brave SR, Charalambous L, Hobbs AJ, Gibson A.

Br J Pharmacol. 1990 Aug;100(4):663-4.

Supplemental Content

Loading ...
Support Center